Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway

Toxicology and Applied Pharmacology

Volumn 272, Issue 1, 2013, Pages 180-190

  Li, Hongzhong ^a   Huang, Jing ^a   Yang, Bing ^a   Xiang, Tingxiu ^a   Yin, Xuedong ^a   Peng, Weiyan ^a   Cheng, Wei ^a   Wan, Jingyuan ^b   Luo, Fuling ^b   Li, Hongyuan ^a   Ren, Guosheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Catenin; Breast cancer; Epithelial mesenchymal transition; Mangiferin; Matrix metalloproteinase

Indexed keywords

BETA CATENIN; GELATINASE B; MANGIFERIN; MATRILYSIN; MATRIX METALLOPROTEINASE; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

Β-CATENIN; BREAST CANCER; DIMETHYL SULFOXIDE; DMSO; ECM; EMT; EPITHELIAL-MESENCHYMAL TRANSITION; ER; ESTROGEN RECEPTOR; EXTRACELLULAR MATRIX; GLYCOGEN SYNTHASE KINASE 3Β; GSK-3Β; IHC; IMMUNOHISTOCHEMISTRY; MANGIFERIN; MATRIX METALLOPROTEINASE; MESENCHYMAL-EPITHELIAL TRANSITION; MET; MMP; PI; PROPIDIUM IODIDE; SD; SP; STANDARD DEVIATION; STREPTAVIDIN-PEROXIDASE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; INDICATORS AND REAGENTS; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; MICE, HAIRLESS; SIGNAL TRANSDUCTION; XANTHONES;

EID: 84882763592     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.05.011     Document Type: Article

References (50)

1. Adams L.S., Phung S., Yee N., Seeram N.P., Li L., Chen S. Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway. Cancer Res. 2010, 70:3594-3605.
2. Beeghly-Fadiel A., Shu X.O., Long J., Li C., Cai Q., Cai H., Gao Y.T., Zheng W. Genetic polymorphisms in the MMP-7 gene and breast cancer survival. Int. J. Cancer 2009, 124:208-214.
3. Biradar S.M., Joshi H., Chheda T.K. Neuropharmacological effect of mangiferin on brain cholinesterase and brain biogenic amines in the management of Alzheimer's disease. Eur. J. Pharmacol. 2012, 683:140-147.
4. Brabletz T., Jung A., Dag S., Reu S., Kirchner T. β-Catenin induces invasive growth by activating matrix metalloproteinases in colorectal carcinoma. Verh. Dtsch. Ges. Pathol. 2000, 84:175-181.
5. Casaburi I., Puoci F., Chimento A., Sirianni R., Ruggiero C., Avena P., Pezzi V. Potential of olive oil phenols as chemopreventive and therapeutic agents against cancer: a review of in vitro studies. Mol. Nutr. Food Res. 2013, 57:71-83.
6. Castillo-Pichardo L., Dharmawardhane S.F. Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer. Nutr. Cancer 2012, 64:1058-1069.
7. Chen P.N., Chu S.C., Kuo W.H., Chou M.Y., Lin J.K., Hsieh Y.S. Epigallocatechin-3 gallate inhibits invasion, epithelial-mesenchymal transition, and tumor growth in oral cancer cells. J. Agric. Food Chem. 2011, 59:3836-3844.
8. Clevers H., Nusse R. Wnt/β-catenin signaling and disease. Cell 2012, 149:1192-1205.
9. Cole L., Anderson M., Antin P.B., Limesand S.W. One process for pancreatic beta-cell coalescence into islets involves an epithelial-mesenchymal transition. J. Endocrinol. 2009, 203:19-31.
10. Crawford H.C., Fingleton B.M., Rudolph-Owen L.A., Goss K.J., Rubinfeld B., Polakis P., Matrisian L.M. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999, 18:2883-2891.
11. Das J., Ghosh J., Roy A., Sil P.C. Mangiferin exerts hepatoprotective activity against d-galactosamine induced acute toxicity and oxidative/nitrosative stress via Nrf2-NFkappaB pathways. Toxicol. Appl. Pharmacol. 2012, 260:35-47.
12. Dave B., Mittal V., Tan N.M., Chang J.C. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012, 14:202.
13. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics, 2011. CA Cancer J. Clin. 2011, 61:409-418.
14. du Plessis-Stoman D., du Preez J., van de Venter M. Combination treatment with oxaliplatin and mangiferin causes increased apoptosis and downregulation of NFkappaB in cancer cell lines. Afr. J. Tradit. Complement. Altern. Med. 2011, 8:177-184.
15. Foroni C., Broggini M., Generali D., Damia G. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat. Rev. 2012, 38:689-697.
16. Garcia D., Leiro J., Delgado R., Sanmartin M.L., Ubeira F.M. Mangifera indica L. extract (Vimang) and mangiferin modulate mouse humoral immune responses. Phytother Res. 2003, 17:1182-1187.
17. Garcia-Rivera D., Delgado R., Bougarne N., Haegeman G., Berghe W.V. Gallic acid indanone and mangiferin xanthone are strong determinants of immunosuppressive anti-tumour effects of Mangifera indica L. bark in MDA-MB231 breast cancer cells. Cancer Lett. 2011, 305:21-31.
18. Gomes L.R., Terra L.F., Sogayar M.C., Labriola L. Epithelial-mesenchymal transition: implications in cancer progression and metastasis. Curr. Pharm. Biotechnol. 2011, 12:1881-1890.
19. Guarino M., Rubino B., Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007, 39:305-318.
20. Guo F., Huang C., Liao X., Wang Y., He Y., Feng R., Li Y., Sun C. Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters. Mol. Nutr. Food Res. 2011, 55:1809-1818.
21. Huang T., Chen Z., Fang L. Curcumin inhibits LPS-induced EMT through downregulation of NF-kappaB-Snail signaling in breast cancer cells. Oncol. Rep. 2013, 29:117-124.
22. 2 levels. J. Biol. Chem. 2011, 286:17649-17657.
23. Jezierska A., Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med. Sci. Monit. 2009, 15:RA32-RA40.
24. Jiang W.G., Davies G., Martin T.A., Parr C., Watkins G., Mason M.D., Mokbel K., Mansel R.E. Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin. Cancer Res. 2005, 11:6012-6019.
25. Jung J.S., Jung K., Kim D.H., Kim H.S. Selective inhibition of MMP-9 gene expression by mangiferin in PMA-stimulated human astroglioma cells: involvement of PI3K/Akt and MAPK signaling pathways. Pharmacol. Res. 2012, 66:95-103.
26. Kim H.S., Song J.H., Youn U.J., Hyun J.W., Jeong W.S., Lee M.Y., Choi H.J., Lee H.K., Chae S. Inhibition of UVB-induced wrinkle formation and MMP-9 expression by mangiferin isolated from Anemarrhena asphodeloides. Eur. J. Pharmacol. 2012, 689:38-44.
27. Li J., Malakhova M., Mottamal M., Reddy K., Kurinov I., Carper A., Langfald A., Oi N., Kim M.O., Zhu F., Sosa C.P., Zhou K., Bode A.M., Dong Z. Norathyriol suppresses skin cancers induced by solar ultraviolet radiation by targeting ERK kinases. Cancer Res. 2012, 72:260-270.
28. Luo J., Deng Z.L., Luo X., Tang N., Song W.X., Chen J., Sharff K.A., Luu H.H., Haydon R.C., Kinzler K.W., Vogelstein B., He T.C. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat. Protoc. 2007, 2:1236-1247.
29. Marchenko N.D., Marchenko G.N., Weinreb R.N., Lindsey J.D., Kyshtoobayeva A., Crawford H.C., Strongin A.Y. Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int. J. Biochem. Cell Biol. 2004, 36:942-956.
30. Marquez L., Garcia-Bueno B., Madrigal J.L., Leza J.C. Mangiferin decreases inflammation and oxidative damage in rat brain after stress. Eur. J. Nutr. 2012, 51:729-739.
31. Mylona E., Kapranou A., Mavrommatis J., Markaki S., Keramopoulos A., Nakopoulou L. The multifunctional role of the immunohistochemical expression of MMP-7 in invasive breast cancer. APMIS 2005, 113:246-255.
32. Paul S., Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma 2008, 55:165-176.
33. Prasad R., Katiyar S.K. Grape seed proanthocyanidins inhibit migration potential of pancreatic cancer cells by promoting mesenchymal-to-epithelial transition and targeting NF-kappaB. Cancer Lett. 2012, 334:118-126.
34. Rajendran P., Ekambaram G., Magesh V., Sakthisekaran D. Chemopreventive efficacy of mangiferin against benzo(a)pyrene induced lung carcinogenesis in experimental animals. Environ. Toxicol. Pharmacol. 2008, 26:278-282.
35. Ranogajec I., Jakic-Razumovic J., Puzovic V., Gabrilovac J. Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med. Oncol. 2012, 29:561-569.
36. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 2009, 27:5287-5297.
37. Rydlova M., Holubec L., Ludvikova M., Kalfert D., Franekova J., Povysil C., Ludvikova M. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer. Res. 2008, 28:1389-1397.
38. Saggar J.K., Chen J., Corey P., Thompson L.U. Dietary flaxseed lignan or oil combined with tamoxifen treatment affects MCF-7 tumor growth through estrogen receptor- and growth factor-signaling pathways. Mol. Nutr. Food Res. 2010, 54:415-425.
39. Sanchez-Tillo E., de Barrios O., Siles L., Cuatrecasas M., Castells A., Postigo A. β-Catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:19204-19209.
40. Scorilas A., Karameris A., Arnogiannaki N., Ardavanis A., Bassilopoulos P., Trangas T., Talieri M. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br. J. Cancer 2001, 84:1488-1496.
41. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61:212-236.
42. Sullu Y., Demirag G.G., Yildirim A., Karagoz F., Kandemir B. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol. Res. Pract. 2011, 207:747-753.
43. Ullah M.F., Ahmad A., Zubair H., Khan H.Y., Wang Z., Sarkar F.H., Hadi S.M. Soy isoflavone genistein induces cell death in breast cancer cells through mobilization of endogenous copper ions and generation of reactive oxygen species. Mol. Nutr. Food Res. 2011, 55:553-559.
44. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 2009, 1796:75-90.
45. Wang S., Kang W., Go M.Y., Tong J.H., Li L., Zhang N., Tao Q., Li X., To K.F., Sung J.J., Yu J. Dapper homolog 1 is a novel tumor suppressor in gastric cancer through inhibiting the nuclear factor-kappaB signaling pathway. Mol. Med. 2012, 18:1402-1411.
46. Wu A.H., Butler L.M. Green tea and breast cancer. Mol. Nutr. Food Res. 2011, 55:921-930.
47. Yao Y.B., Peng Z.G., Liu Z.F., Yang J., Luo J. Effects of mangiferin on cell cycle status and CDC2/Cyclin B1 expression of HL-60 cells. Zhong Yao Cai 2010, 33:81-85.
48. Yoshimi N., Matsunaga K., Katayama M., Yamada Y., Kuno T., Qiao Z., Hara A., Yamahara J., Mori H. The inhibitory effects of mangiferin, a naturally occurring glucosylxanthone, in bowel carcinogenesis of male F344 rats. Cancer Lett. 2001, 163:163-170.
49. Zhang X., Su B., Li J., Li Y., Lu D., Zhu K., Pei H., Zhao M. Analysis by RP-HPLC of mangiferin component correlation between medicinal loranthus and their mango host trees. J. Chromatogr. Sci 2012, 10.1093/chromsci/bms196.
50. Zhao J.H., Luo Y., Jiang Y.G., He D.L., Wu C.T. Knockdown of beta-catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1alpha. Cancer Invest. 2011, 29:377-382.